Highest-materiality recent filing
Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.
Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026
Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.
Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026
Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).
Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share
Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.
Candel enters $100M royalty funding deal with RTW; funds available upon FDA approval of CAN-2409 for localized prostate cancer.
Candel Q3 net loss $11.3M; cash $87M; secures $130M debt facility with Trinity Capital
Net loss of $11.3M vs $10.6M in Q3 2024; R&D expenses $8.5M, G&A $4.7M.
Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data
Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.
Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.
Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67
Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.
FDA grants RMAT designation to Candel's CAN-2409 for prostate cancer; phase 3 met endpoint
RMAT designation for CAN-2409 (aglatimagene besadenovec) in newly diagnosed localized intermediate-to-high-risk prostate cancer.
Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.
Candel Therapeutics Q1 net income $7.4M; cash runway into Q1 2027; CAN-2409 BLA on track
Net income of $7.4M in Q1 2025 vs net loss of $8.2M in Q1 2024, driven by warrant liability fair value change.
Phase 3 CAN-2409 data in localized prostate cancer accepted for oral presentation at ASCO 2025 (May 30-June 3, Chicago).
mOS of 24.5 months in evaluable patients (cohort 1+2, n=46) with advanced NSCLC inadequately responding to ICI.
Positive phase 3 results for CAN-2409 in prostate cancer: 30% risk reduction, 80.4% pathological complete responses; BLA submission expected Q4 2026.
Candel: CAN-2409 final phase 2 data shows median OS 31.4 mo vs 12.5 mo in pancreatic cancer
Estimated median overall survival 31.4 months in CAN-2409 arm vs 12.5 months in control (borderline resectable PDAC).
Candel Therapeutics reports $102.9M cash; updates on CAN-2409 BLA timeline and 2025 milestones
Cash and equivalents $102.9M (unaudited) at Dec 31, 2024, vs $35.4M at end-2023; provides runway into Q1 2027.
Candel prices $80M public offering of common stock and pre-funded warrants at $6.00/share
Offering: 10,000,001 common shares at $6.00/share plus pre-funded warrants for 3,333,333 shares at $5.99/warrant.
Candel's CAN-2409 meets phase 3 prostate cancer endpoint; BLA submission targeted for Q4 2026
Phase 3 trial met primary endpoint: DFS improvement with HR 0.7 (p=0.0155) vs placebo in intermediate-to-high risk localized prostate cancer.
Candel Therapeutics Q3 net loss $10.6M, cash $16.6M; key prostate cancer data on track for Q4 2024
Net loss of $10.6M in Q3 2024 vs $8.4M in Q3 2023; includes $1.9M other expense from warrant liability.
Candel reports 3 of 6 rHGG patients alive >1 year after CAN-3110 multiple injections
Phase 1b trial of CAN-3110 in recurrent high-grade glioma: 3/6 patients alive at 12.2, 13.0, and 18.7 months post-treatment.
Candel Therapeutics Q2 net loss $22.2M; cash runway into Q1 2025; positive CAN-2409 pancreatic data
Net loss of $22.2M in Q2 2024 vs $9.6M in Q2 2023; includes $13.7M non-cash warrant liability adjustment.
Candel reports Phase 2 CAN-2409 data: 20.6-month median OS in NSCLC patients with ICI resistance
Median overall survival of 20.6 months in NSCLC patients with progressive disease despite ICI, vs 11.6 months historical SoC docetaxel.
Candel Therapeutics Q1 net loss $8.2M; highlights positive CAN-2409 pancreatic cancer survival data
Net loss $8.2M vs $8.8M YoY; R&D expenses $4.1M, G&A $3.8M.
Candel Therapeutics receives FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer
FDA granted Orphan Drug Designation for CAN-2409 (multimodal immunotherapy) in pancreatic cancer.
Candel reports CAN-2409 phase 2 interim data: median OS 28.8 vs 12.5 months in pancreatic cancer
Estimated median overall survival 28.8 months for CAN-2409 group vs 12.5 months for control in borderline resectable PDAC.
Candel receives FDA Fast Track Designation for CAN-3110 in recurrent high-grade glioma
FDA granted Fast Track Designation for CAN-3110, an HSV-1 oncolytic viral immunotherapy for recurrent HGG to improve overall survival.
Candel Therapeutics CFO Jason Amello resigns; Charles Schoch appointed interim CFO
Jason Amello resigned as CFO, principal financial and accounting officer, effective January 12, 2024, to pursue another opportunity.
FDA grants Fast Track Designation to Candel's CAN-2409 for pancreatic cancer
FDA Fast Track Designation for CAN-2409 (adenovirus immunotherapy) plus valacyclovir in pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.
Approximately 50% workforce reduction; one-time restructuring charge of ~$0.7M in Q4 2023.
Candel Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified CADL that bid price below $1.00 for 30 consecutive business days.
Candel Therapeutics Q3 2023 net loss $8.4M; cash runway into Q2 2024
Net loss of $8.4M in Q3 2023, versus $8.7M loss in Q3 2022; no revenue recognized.
Estimated overall survival rate 71.4% at 24 & 36 months for CAN-2409 arm vs 16.7% control in borderline resectable PDAC.
Candel announces Nature publication: CAN-3110 extends survival in recurrent high-grade glioma
Phase 1 trial (n=41) of CAN-3110 in recurrent HGG showed median OS of 11.6 months, nearly double historical 6-9 months.
On June 20, 2025, the board of directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Charles Schoch as the Company’s Chief Financial Officer, effective June 20, 2025
On June 4, 2025, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) directors and unanimously appointed Maha Radhakrishnan, M.D., to fill the newly created vacancy on the Board, effective June 4, 2025.
Jason A. Amello resigned from his position as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity.
unanimously appointed Charles Schoch as the Company’s interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024.
Effective upon Mr. Amello’s cessation of service as Chief Financial Officer, the Company intends to appoint Charles Schoch, the Company’s current Vice President of Finance and Corporate Controller, as the Company’s Interim Chief Financial Officer, principal financial and principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Amello.
On December 11, 2023, Jason A. Amello notified Candel Therapeutics, Inc. (the “Company”) of his decision to resign from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024, to pursue another opportunity.
unanimously appointed Nicoletta Loggia, Ph.D., R.Ph., to fill the newly created vacancy on the Board, effective June 7, 2023.
On September 6, 2022, Candel Therapeutics, Inc. (the “Company”) accepted the resignation of John Canepa as the Company’s Chief Financial Officer, effective September 21, 2022.
Jason Amello as the Company’s Chief Financial Officer, effective September 21, 2022.
appointed Garrett Nichols. M.D., M.S., as the Company’s Chief Medical Officer, effective September 12, 2022
The Board unanimously appointed Renee Gaeta, Dr. Gary Nabel and Joseph Papa, effective August 8, 2022, to fill the newly created vacancies on the Board resulting from the resignations of Dr. Gandhi, Dr. Meirav and Dr. Smith.
The Board unanimously appointed Renee Gaeta, Dr. Gary Nabel and Joseph Papa, effective August 8, 2022, to fill the newly created vacancies on the Board resulting from the resignations of Dr. Gandhi, Dr. Meirav and Dr. Smith.
Max materiality 0.90 · Median 0.65 · Most common event other_material